Department of Psychiatry, Imam Hossein Hospital, School of Medicine, Alborz University of Medical Sciences, Karaj, Alborz, Iran.
Non-communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran.
Psychopharmacology (Berl). 2024 Jul;241(7):1463-1476. doi: 10.1007/s00213-024-06577-x. Epub 2024 Mar 21.
Changes in the density and diversity of gut microbiota in chronic use of methamphetamine have been mentioned as contributors to psychotic and anxiety symptoms, sleep problems, and loss of appetite.
In this placebo-controlled clinical trial, we investigated the effect of the probiotic Lactobacillus Acidophilus in improving psychiatric symptoms among hospitalized patients with chronic methamphetamine use along with psychotic symptoms.
60 inpatients with a history of more than 3 years of methamphetamine use, were randomly assigned to one of two groups receiving either a probiotic capsule or placebo along with risperidone for 8 weeks based on a simple randomization method. In weeks 0, 4, and 8, patients were evaluated using the Brief Psychiatric Rating Scale (BPRS), Beck Anxiety Inventory (BAI), Pittsburgh Sleep Quality Index (PSQI), Simple Appetite Nutritional Questionnaire (SANQ), and Body Mass Index (BMI).
Compared to the control group, patients receiving probiotics had better sleep quality, greater appetite, and higher body mass index (there were significant interaction effects of group and time at Week 8 in these variables (t = -3.32, B = -1.83, p = .001, d = 0.89), (t = 10.50, B = 2.65, p <.001, d = 1.25) and (t = 3.40, B = 0.76, p <.001, d = 0.30), respectively. In terms of the improvement of psychotic and anxiety symptoms, there was no statistically significant difference between the two groups.
The use of probiotics was associated with improved sleep quality, increased appetite, and increased body mass index in patients with chronic methamphetamine use. Conducting more definitive clinical trials with larger sample sizes and longer-term follow-up of cases is recommended.
慢性使用甲基苯丙胺会导致肠道微生物群的密度和多样性发生变化，这被认为是导致精神病和焦虑症状、睡眠问题以及食欲不振的原因之一。
在这项安慰剂对照的临床试验中，我们研究了嗜酸乳杆菌益生菌对改善有精神病症状的慢性甲基苯丙胺使用住院患者的精神症状和焦虑症状的效果。
将 60 名有超过 3 年甲基苯丙胺使用史的住院患者随机分为两组，每组 30 名，分别接受益生菌胶囊或安慰剂联合利培酮治疗 8 周。在第 0、4 和 8 周，使用简明精神病评定量表（BPRS）、贝克焦虑量表（BAI）、匹兹堡睡眠质量指数（PSQI）、简单食欲营养问卷（SANQ）和体重指数（BMI）对患者进行评估。
与对照组相比，接受益生菌治疗的患者睡眠质量更好，食欲更好，体重指数更高（在第 8 周时，这些变量的组间和时间存在显著的交互效应（t = -3.32，B = -1.83，p =.001，d = 0.89），（t = 10.50，B = 2.65，p <.001，d = 1.25）和（t = 3.40，B = 0.76，p <.001，d = 0.30）。在改善精神病和焦虑症状方面，两组之间没有统计学上的显著差异。
在慢性甲基苯丙胺使用患者中，使用益生菌与改善睡眠质量、增加食欲和增加体重指数有关。建议进行更大规模、更长时间随访的更明确的临床试验。
